Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis
About This Grant
Project Summary/Abstract Triple-negative breast cancer is an aggressive subtype of breast cancer that tends to metastasize to distant organs early in the course of the disease. Metastasis can occur by cancer cells from the breast tumor directly entering the blood to travel to distant organs (hematogenous metastasis), or by cancer cells spreading from the breast tumor to nearby lymph nodes, and then leaving the lymph nodes to enter the blood and travel to distant organs (lymphatic metastasis). We are interested in understanding how lymphatic metastasis occurs. Cancer cells change their gene expression in order to promote metastasis. One way that cancer cells can regulate gene expression is through the action of noncoding RNAs. We found that the noncoding RNA Snord67 promotes lymphatic metastasis in a mouse model of triple-negative breast cancer. Snord67 is a small nucleolar RNA (snoRNA) that leads to the 2′-O-methylation of another noncoding RNA, U6 small nuclear RNA (snRNA). However, it is unknown whether Snord67 promotes metastasis by increasing the methylation of U6 snRNA or through other, unknown mechanisms. For example, some snoRNAs are known to promote the 2′-O-methylation of protein-coding messenger RNAs (mRNAs), which can lead to changes in mRNA processing, stability, or translation into proteins. The goal of this proposal is to determine whether Snord67 promotes lymphatic metastasis by increasing the methylation of U6 snRNA or by performing other functions, such as increasing the methylation of mRNAs. This proposal includes two aims: (1) Determine the functional importance of Snord67- guided 2′-O-methylation of U6 snRNA at C60 (canonical mechanism) in the promotion of lymphatic metastasis by Snord67, and (2) Determine the contribution of Snord67-guided 2′-O-methylation of target mRNAs (non- canonical mechanism) to the promotion of lymphatic metastasis by Snord67. These studies will help us better understand how triple-negative breast cancer spreads and could potentially lead to new approaches for treating or preventing breast cancer metastasis. The trainee will work in a highly productive multidisciplinary scientific environment and develop proficiency in a variety of experimental methods in RNA biology and cancer biology under the mentorship of physician–scientist experts.
Grant Summary
Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis is a NCI - National Cancer Institute grant providing up to $88K for university, nonprofit, healthcare org. Applications are due 2027-01-17 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $88K
2027-01-17
- 1Confirm your organization is eligible for Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis: Frequently Asked Questions
Who is eligible for the Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis?
Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis provide?
Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis provides up to $88K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis deadline?
Applications for Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis are due 2027-01-17 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis?
To apply for Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.